The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States-Reference-Cited by-同舟云学术

The cost-effectiveness of testing for NS5a resistance-associated polymorphisms at baseline in genotype 1a-infected (treatment-naïve and treatment-experienced) subjects treated with all-oral elbasvir/grazoprevir regimens in the United States

Published:2016-12-01 Issue:3 Volume:45 Page:455-467
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Elbasha E. H.¹,Robertson M. N.¹,Nwankwo C.¹

Affiliation:

1. Merck & Co., Inc.; Kenilworth NJ USA

Funder

Merck

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13882/fullpdf

Reference64 articles.

1. Chronic hepatitis C virus (HCV) disease burden and cost in the United States;Razavi;Hepatology,2013

2. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States;Nainan;Gastroenterology,2006

3. ZEPATIER's product label http://www.merck.com/product/usa/pi_circulars/z/zepatier/zepatier_pi.pdf

4. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis c virus genotype 1, 4, or 6 infection: a randomized trial;Zeuzem;Ann Intern Med,2015

5. The prevalence and the effect of HCV NS5A resistance associated variants in subjects with compensated cirrhosis treated with ledipasvir/sofosbuvir +/− RBV;Sarrazin;J Hepatol,2015

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-Effectiveness of Elbasvir/Grazoprevir for the Treatment of Chronic Hepatitis C: A Systematic Review;Frontiers in Public Health;2022-05-13

2. Cost-Effectiveness of Testing for NS5A Resistance to Optimize Treatment of Elbasvir/Grazoprevir for Chronic Hepatitis C in China;Frontiers in Pharmacology;2021-10-15

3. Cost–Utility of All-Oral Direct-Acting Antiviral Regimens for the Treatment of Genotype 1 Chronic Hepatitis C Virus-Infected Patients in Hong Kong;Digestive Diseases and Sciences;2020-05-08

4. Cost-Effectiveness Analysis of Baseline Testing for Resistance-Associated Polymorphisms to Optimize Treatment Outcome in Genotype 1 Noncirrhotic Treatment-Naïve Patients With Chronic Hepatitis C Virus;Value in Health;2020-02

5. Epidemiology of hepatitis C virus infection in a country with universal access to direct‐acting antiviral agents: Data for designing a cost‐effective elimination policy in Spain;Journal of Viral Hepatitis;2019-12-06